The cellular and molecular heterogeneity of the aggressive non-Hodgkin's lymphomas

Current Opinion in Oncology

Volumn 10, Issue 5, 1998, Pages 385-391

  Howard, Orion M ^a   Shipp, Margaret A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER MORTALITY; CELL HETEROGENEITY; CLINICAL FEATURE; GENETIC HETEROGENEITY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 0031730752     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199809000-00003     Document Type: Review

References (46)

1. Shipp M, Harrington DP, Anderson J, Armitage J, Bonnadonna G, Brittinger G, et al.: A predictive model for aggressive non-Hodgkin's lymphoma: The International non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993, 329:987-994.
2. Harris N, Jaffe E, Stein H, Banks P, Chan J, Cleary M, et al.: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994, 84:1361-1392.
3. Armitage J, for The Non-Hodgkin's Lymphoma Classification Project: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997, 89:3909-3918. The incidence and natural history of entities defined by the REAL classification are described.
4. Engelhard M, Brittinger G, Huhn D, Gerhartz H, Meusers P, Siegert W, et al.: Subclassification of diffuse large B-cell lymphomas according to the Kiel Classification: Distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor. Blood 1997, 89:2291-2297.
5. Lazzarino M, Orlandi E, Paulli M, Strater J, Klersy C, Gianelli U, et al.: Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: A multicenter study of 106 patients. J Clin Oncol 1997, 15:1646-1653. Primary mediastinal B-cell lymphomas are compared and contrasted with other diffuse large B-cell lymphomas.
6. Majlis A, Pugh W, Rodriguez M, Benedict W, Cabanillas F: Mantle cell lymphoma: Correlation of clinical outcome and biologic features with three histologie variants. J Clin Oncol 1997, 15:1664-1671.
7. Melnyk A, Rodriguez A, Pugh W, Cabanillas F: Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 1997, 89:4514-4520. The prognostic significance of immunophenotyping (B-cell vs T-cell) in aggressive NHLs is demonstrated.
8. Ansell S, Habermann T, Kurtin P, Witzig T, Chen M, Li C, et al.: Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. J Clin Oncol 1997, 15:2296-2301.
9. Kwong Y, Chan A, Liang R, Chiang A, Chim C, Chan T, et al.: CD56+ NK lymphomas: Clinicopathological features and prognosis. Br J Haematol 1997, 97:821-829.
10. Chan J, Sin V, Wong K, Ng C, Tsang W, Chan C, et al.: Nonnasal lymphoma expressing the natural killer cell marker CD56: A clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood 1997, 89:4501-4513.
11. Tilly H, Gaulard P, Lepage E, Dumontet C, Diebold J, Plantier I, et al.: Primary anaplastic large-cell lymphoma in adults: Clinical presentation, immunophenotype, and outcome. Blood 1997, 90:3727-3734.
12. Janicek M, Kaplan W, Neuberg D, Canellos G, Shulman L, Shipp M: Early restaging gallium scans predict outcome in poor prognosis patients with aggressive non-Hodgkin's lymphoma who are treated with high dose CHOP chemotherapy. J Clin Oncol 1997, 15:1631-1637. The rapidity of responses to therapy are assessed with early restaging gallium scans and shown to predict outcome in aggressive NHL.
13. Kapucu L, Akyuz C, Vural G, Oguz A, Atasever T, Buyukpamukcu M, Unlu M: Evaluation of therapy response in children with untreated malignant lymphomas using technetium-99m-sestamibi. J Nucl Med 1997, 38:243-247.
14. Heidebrecht H, Buck F, Steinmann J, Sprenger R, Wacker H, Parwaresch R: p100: A novel proliferation-associated nuclear protein specifically restricted to cell cycle phases S, G2, and M. Blood 1997, 90:226-233.
15. Ristamaki R, Joesuu H, Lappalainen K, Teerenhovi L, Jalkanen S: Elevated serum CD44 level is associated with unfavorable outcome in non-Hodgkin's lymphoma. Blood 1997, 90:4039-4045. Serum levels of (shed) CD44 are found to correlate with risk of death from aggressive NHL
16. Yakushijin Y, Steckel J, Kharbanda S, Hasserjian R, Neuberg D, Jiang W-M, et al.: A directly spliced exon 10-containing CD44 variant promotes the metastasis and homotypic aggregation of aggressive non-Hodgkin's lymphoma. Blood 1998, 91:4282-4291.
17. Terol M-J, Lopez-Guillermo A, Bosch F, Villamor N, Cid M-C, Rozman C, et al.: Expression of the adhesion molecule ICAM-1 in non-Hodgkin's lymphoma: Relationship with tumor dissemination and prognostic importance. J Clin Oncol 1998, 16:35-40. In this series, aggressive NHLs with low ICAM-1 expression are more likely to present as disseminated disease and to be associated with shortened survival.
18. Weimar I, de Jong D, Muller E, Nakamura T, van Gorp J, de Gast G, Gerritsen W: Hepatocyte growth factor/scatter factor promotes adhesion of lymphoma cells to extracellular matrix molecules via a4b1 and a5b1 integrins. Blood 1997, 89:990-1000.
19. Stetler-Stevenson M, Mansoor A, Lim M, Fukushima P, Kehri J, Marti G, et al.: Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in reactive and neoplastic lymphoid cells. Blood 1997, 89:1708-1715.
20. Kossakowska A, Urbanski S, Huchcroft S, Edwards D: Relationship between the clinical aggressiveness of large cell immunoblastic lymphomas and expression of 92 kDa gelatinase (type IV collagenase) and tissue inhibitor of metalloproteinases-1 (TIMP-1) RNAs. Oncol Res 1992, 4:233-240.
21. Kossakowska A, Hinek A, Edwards D, Lim M, Zhang C-L, Breitman C, et al: Proteolytic activity of human non-Hodgkin's lymphomas. Am J Pathol 1998, 152:565-576.
22. Kruger A, Fata J, Khokha R: Altered tumor growth and metastasis of a T-cell lymphoma in TIMP-1 transgenic mice. Blood 1997, 90:1993-2000.
23. Salven P, Teerenhovi L, Joensuu H: A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 1997, 90:3167-3172. Elevated serum levels of VEGF are associated with an increased risk of death and with other clinical parameters included in the IPI.
24. Preti H, Cabanillas F, Talpaz, M, Tucker S, Seymour J, Kurzrock R: Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med 1997, 127:186-194. Elevated serum IL-6 levels are associated with other clinical risk factors included in the IPI. Addition of IL-6 to the IPI increases the predictive value of the model.
25. Warzocha K, Salles G, Bienvenu J, Barbier Y, Bastion Y, Doche C, et al.: Prognostic significance of TNFa and its p55 soluble receptor in malignant lymphomas. Leukemia 1997, 11(suppl):441-443.
26. Warzocha K, Salles G, Bienvenu J, Bastion Y, Dumontet C, Renard N, et al.: Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients. J Clin Oncol 1997, 15:499-508. Elevated levels of TNF and its soluble receptors are associated with advanced stage disease and shorter overall survivals.
27. Ambrosini G, Adida C, Altieri D: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nature Med 1997, 3:917-921. A novel inhibitor of apoptosis is identified and found to be expressed in many aggressive NHLs.
28. Uchimaru K, Taniguchi T, Yoshikawa M, Asano S, Arnold A, Fujita T, Motokura T: Detection of cyclin D1 (bcl-1, PRAD1) overexpression by a simple competitive reverse transcription-polymerase chain reaction assay in t(11;14)(q13;a32)-bearing B-cell malignancies and/or mantle cell lymphoma. Blood 1997, 89:965-974.
29. Ott G, Kalla J, Ott M, Schryen B, Katzenberger T, Muller J, Muller-Hermelink H: Blastoid variants of mantle cell lymphoma: Frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. Blood 1997, 89:1421-1429. The cellular and molecular features of the blastoid variant of mantle cell lymphoma are described.
30. Gascoyne R, Adomat S, Krajewski S, Krajewska M, Horsman D, Tolcher A, et al.: Prognostic significance of bcl-2 protein expression and bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997, 90:244-251. In this series of aggressive NHLs, bcl-2 rearrangements are not associated with outcome; in contrast, the overexpression of bcl-2 protein is associated with shortened survival.
31. Monni O, Joensuu H, Franssila K, Klefstrom J, Alitalo K, Knuutila S: Bcl2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. Blood 1997, 90:1168-1174.
32. Gascoyne R, Krajewska M, Krajewski S, Connors J, Reed J: Prognostic significance of bax protein expression in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997, 90:3173-3178.
33. Fukuda T, Yoshida T, Okada S, Hatano M, Miki T, Ishibashi K, et al.: Disruption of the Bcl6 gene results in an impaired germinal center formation. J Exp Med 1997, 186:439-448. The bcl-6 gene is shown to be necessary for normal germinal center formation.
34. Chen W, Iida S, Louie D, Dalla-Favera R, Chaganti R: Heterologous promoters fused to BCL6 by chromosomal translocations affecting band 3q27 cause its deregulated expression during B-cell differentiation. Blood 1998, 91:603-607.
35. Ye B, Cattoretti G, Shen Q, Zhang J, Hawe N, de Waard R, et al.: The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet 1997, 16:161-170. The bcl-6 gene is shown to be necessary for normal germinal center formation.
36. Pescarmona E, De Sanctis V, Pistilli A, Pacchiarotti A, Martelli M, Guglielmi C, et al.: Pathogenetic and clinical implications of Bcl-6 and Bcl-2 gene configuration in nodal diffuse large B-cell lymphomas. J Pathol 1997, 183:281-286.
37. Butler M, Corbally N, Dervan P, Carney D: Bcl-6 and other genomic alternations in non-Hodgkin's lymphoma (NHL). Br J Cancer 1997, 75:1641-1645.
38. Mathew P, Sanger W, Weisenburger D, Valentine M, Valentine V, Pickering D, et al.: Detection of the t(2;5)(p23;q35) and NPM-ALK fusion in non-Hodgkin's lymphoma by two-color fluorescence in situ hybridization. Blood 1997, 89:1678-1685.
39. Morris S, Naeve C, Mathew P, James P, Kirstein M, Cui X, Witte D: ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 1997, 14:2175-2188. Anaplastic lymphoma kinase is further characterized in this paper.
40. Nakamura S, Shiota M, Nakagawa A, Yatabe Y, Kojima M, Motoori T, et al.: Anaplastic large cell lymphoma: A distinct molecular pathologic entity. Am J Surg Pathol 1997, 21:1420-1432.
41. Delsol G, Lamant L, Mariame B, Pulford K, Dastugue N, Brousset P, et al.: A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation. Blood 1997, 89:1483-1490.
42. Koduru P, Raju K, Vadmal V, Menezes G, Shah S, Susin M, et al.: Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma. Blood 1997, 90:4078-4091.
43. Ichkawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K, et al.: Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 1997, 337:529-534. Mutations of the p53 gene are found to be highly correlated with detectable p53 expression; both parameters are associated with shortened overall survival.
44. Garcia-Sanz R, Gonzalez M, Vargas M, Chillon M, Balanzategui A, Barbon M, et al.: Deletions and rearrangements of cyclin-dependent kinase 4 inhibitor gene p16 are associated with poor prognosis in B cell non-Hodgkin's lymphomas. Leukemia 1997, 11:1915-1920.
45. Horenstein M, Nador R, Chadburn A, Hyjek E, Inghirami G, Knowles D, Cesarman E: Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated Herpesvirus/human Herpesvirus-8. Blood 1997, 90:1186-1191.
46. Cheng E-Y, Nicholas J, Bellows D, Hayward G, Guo H-G, Reitz M, Hardwick J: A bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with bax and bak. Proc Natl Acad Sci U S A 1997, 94:690-694.